EA202192344A1 - Тритерпеноидные фунгициды для лечения или предотвращения пневмоцистной пневмонии, вызванной pneumocystis spp - Google Patents

Тритерпеноидные фунгициды для лечения или предотвращения пневмоцистной пневмонии, вызванной pneumocystis spp

Info

Publication number
EA202192344A1
EA202192344A1 EA202192344A EA202192344A EA202192344A1 EA 202192344 A1 EA202192344 A1 EA 202192344A1 EA 202192344 A EA202192344 A EA 202192344A EA 202192344 A EA202192344 A EA 202192344A EA 202192344 A1 EA202192344 A1 EA 202192344A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
triterpenoid
pneumocystis spp
pneumocystispneumonia
Prior art date
Application number
EA202192344A
Other languages
English (en)
Russian (ru)
Inventor
Давид А. Ангуло Гонсалес
Стефен Эндрю Барат
Original Assignee
Сайнексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайнексис, Инк. filed Critical Сайнексис, Инк.
Publication of EA202192344A1 publication Critical patent/EA202192344A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA202192344A 2019-02-27 2020-02-25 Тритерпеноидные фунгициды для лечения или предотвращения пневмоцистной пневмонии, вызванной pneumocystis spp EA202192344A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (1)

Publication Number Publication Date
EA202192344A1 true EA202192344A1 (ru) 2021-11-15

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192344A EA202192344A1 (ru) 2019-02-27 2020-02-25 Тритерпеноидные фунгициды для лечения или предотвращения пневмоцистной пневмонии, вызванной pneumocystis spp

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
KR20210133241A (ko) 2021-11-05
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
JP7581219B2 (ja) 2024-11-12
AU2020228036B2 (en) 2025-08-07
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
CN113631165A (zh) 2021-11-09
BR112021016876A2 (pt) 2021-11-03
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
ECSP12012002A (es) Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
EA201691336A1 (ru) Способ лечения фибрилляции предсердий
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
NO20073774L (no) Terapeutiske forbindelser for intranasal administrering av ketorolac
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2024002409A (es) Terapias contra el cancer.
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2022012001A (es) Tratamiento preventivo de la migra?a.
EA202192344A1 (ru) Тритерпеноидные фунгициды для лечения или предотвращения пневмоцистной пневмонии, вызванной pneumocystis spp
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
WO2020101790A3 (en) Methods of using a phenoxypropylamine compound to treat pain
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
MX2019012116A (es) Agentes antifungicos utilizados en combinacion.
Andersen et al. sGC–cGMP–PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury